James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Wait on Arena’s Weight-Loss Drug

The FDA is all set to rule on Arena Pharmaceuticals' weight loss drug lorcaserin, and things look good, but its approval might already be priced in.

Don’t Buy Pharma Stocks — Buy THESE Pharma Stocks

If your sliver of the pharma pie is too small, it's easy to fall into the "any old pharma stock will do" trap. Keep your eye on the prize with these must-own names.

5 More CEOs Who Should Apologize

JPMorgan's Jamie Dimon and GM's Dan Akerson recently owned up to corporate faults (to some extent). But here are five more CEOs that should pipe up.

Apple Knocks Garmin’s Turnaround Story Off the Road

With the gap between smartphones and GPS devices, Garmin didn't seem to be in that bad of shape. Or it didn't until Monday, that is.

Too Little, Too Late for Chesapeake?

Chesapeake's sale of pipeline assets sacrifices key cash generators for a short-term patch. It might work; or it might be the beginning of the end.